Payment overview · 2025
General Payments
$344.15
18 reported records · 9 companies
Healthcare provider profile · identity verified
Taylor Renea Carson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ENID, OK · NPI 1619433547
Verified facts
What the public records show
CMS Open Payments records show Taylor Renea Carson, PA-C received $344.15 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.11 | 25.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.87 | 19.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.88 | 11.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.81 | 9.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.46 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.78 | 9.2% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.07 | 5.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.59 | 4.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.58 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.15 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.87 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $60.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.78 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.11 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 145 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 139 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 42 |
| Gabapentin | Gabapentin | 102 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 96 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 29 |
| Meloxicam | Meloxicam | 82 | 28 |
| Trulicity | Dulaglutide | 71 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 25 |
| Losartan Potassium | Losartan Potassium | 68 | 24 |
| Furosemide | Furosemide | 63 | 19 |
| Sertraline Hcl | Sertraline Hcl | 59 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 15 |
| Famotidine | Famotidine | 44 | 13 |
| Montelukast Sodium | Montelukast Sodium | 43 | 12 |
| Carvedilol | Carvedilol | 42 | 13 |
| Ozempic | Semaglutide | 42 | 15 |
| Metformin Hcl | Metformin Hcl | 41 | 16 |
| Omeprazole | Omeprazole | 39 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Prednisone | Prednisone | 37 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 20 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 17 |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 32 | 11 |
| Potassium Chloride | Potassium Chloride | 31 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Simvastatin | Simvastatin | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Dotti | Estradiol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.15 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEYFORTUS, BREZTRI, CAPLYTA, Cologuard Collection Kit, FLUZONE HIGH-DOSE, MAVYRET, MOUNJARO, QULIPTA, REXULTI, VAXELIS, YUPELRI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error